J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, vol.136, pp.359-386, 2015.

C. R. Leemans, P. J. Snijders, and R. H. Brakenhoff, The molecular landscape of head and neck cancer, Nat. Rev. Cancer, vol.18, pp.269-282, 2018.

A. Argiris, K. J. Harrington, M. Tahara, J. Schulten, P. Chomette et al., Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Front, vol.7, p.72, 2017.

J. A. Bonner, P. M. Harari, J. Giralt, N. Azarnia, D. M. Shin et al., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N. Engl. J. Med, vol.354, pp.567-578, 2006.

C. H. Chung, J. S. Parker, G. Karaca, J. Wu, W. K. Funkhouser et al., Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression, Cancer Cell, vol.5, pp.489-500, 2004.

V. Walter, X. Yin, M. D. Wilkerson, C. R. Cabanski, N. Zhao et al., Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes, PLoS ONE, vol.8, 2013.

, Comprehensive genomic characterization of head and neck squamous cell carcinomas, Nature, vol.517, pp.576-582, 2015.

M. K. Keck, Z. Zuo, A. Khattri, T. P. Stricker, C. D. Brown et al., Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes, Clin. Cancer Res, vol.21, pp.870-881, 2015.

L. De-cecco, M. Nicolau, M. Giannoccaro, M. G. Daidone, P. Bossi et al., Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data, Oncotarget, vol.6, pp.9627-9642, 2015.

P. Bossi, C. Bergamini, M. Siano, M. Cossu-rocca, A. P. Sponghini et al., Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab, Clin. Cancer Res, vol.22, pp.3961-3970, 2016.

W. Yang, J. Soares, P. Greninger, E. J. Edelman, H. Lightfoot et al., Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells, Nucleic Acids Res, vol.41, pp.955-961, 2013.

C. Boeckx, M. Baay, A. Wouters, P. Specenier, J. B. Vermorken et al., Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: Focus on potential molecular mechanisms of drug resistance, Oncologist, vol.18, pp.850-864, 2013.

B. Singh, G. Carpenter, and R. J. Coffey, EGF receptor ligands: Recent advances, vol.5, 2016.

D. J. Riese and R. L. Cullum, Epiregulin: Roles in normal physiology and cancer, Semin. Cell Dev. Biol, vol.28, pp.49-56, 2014.

N. Sunaga and K. Kaira, Epiregulin as a therapeutic target in non-small-cell lung cancer, Lung Cancer, vol.6, pp.91-98, 2015.

J. Yang, S. Li, B. Wang, Y. Wu, Z. Chen et al., Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer, Tumour Biol. J. Int. Soc. Oncodev. Biol. Med, vol.37, pp.11645-11655, 2016.

L. Tonella, M. Giannoccaro, S. Alfieri, S. Canevari, and L. De-cecco, Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application?, Curr. Treat. Options Oncol, vol.18, 2017.

A. C. Jung, S. Job, S. Ledrappier, C. Macabre, J. Abecassis et al., A poor prognosis subtype of HNSCC is consistently observed across methylome, transcriptome, and miRNome analysis, Clin. Cancer Res, vol.19, pp.4174-4184, 2013.

C. Berasain and M. A. Avila, Amphiregulin. Semin. Cell Dev. Biol, vol.28, pp.31-41, 2014.

M. J. Garnett, E. J. Edelman, S. J. Heidorn, C. D. Greenman, A. Dastur et al., Systematic identification of genomic markers of drug sensitivity in cancer cells, Nature, vol.483, pp.570-575, 2012.

J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A. A. Margolin et al., The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, vol.483, pp.603-607, 2012.

V. D'amato, R. Rosa, C. D'amato, L. Formisano, R. Marciano et al., The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models, Br. J. Cancer, vol.110, pp.2887-2895, 2014.

P. M. Harari, D. L. Wheeler, and J. R. Grandis, Molecular target approaches in head and neck cancer: Epidermal growth factor receptor and beyond, Semin. Radiat. Oncol, vol.19, pp.63-68, 2009.

D. Soulieres, N. N. Senzer, E. E. Vokes, M. Hidalgo, S. S. Agarwala et al., Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck, J. Clin. Oncol, vol.22, pp.77-85, 2004.

J. P. Machiels, R. I. Haddad, J. Fayette, L. F. Licitra, M. Tahara et al., Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): An open-label, randomised phase 3 trial, Lancet Oncol, vol.16, pp.583-594, 2015.

R. G. Martins, U. Parvathaneni, J. E. Bauman, A. K. Sharma, L. E. Raez et al., Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase II trial, J. Clin. Oncol, vol.31, pp.1415-1421, 2013.

Y. Kawaguchi, K. Kono, K. Mimura, H. Sugai, H. Akaike et al., Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma, Int. J. Cancer, vol.120, pp.781-787, 2007.

L. Lattanzio, N. Denaro, D. Vivenza, C. Varamo, G. Strola et al., Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy, Cancer Immunol. Immunother, vol.66, pp.573-579, 2017.

E. E. Cohen, L. F. Licitra, B. Burtness, J. Fayette, T. Gauler et al., Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer, Ann. Oncol, vol.28, pp.2526-2532, 2017.

Y. Sato-kuwabara, J. I. Neves, J. H. Fregnani, R. A. Sallum, and F. A. Soares, Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry, BMC Cancer, vol.9, issue.6, 2009.

W. Xia, Y. K. Lau, H. Z. Zhang, A. R. Liu, L. Li et al., Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma, Clin. Cancer Res, vol.3, pp.3-9, 1997.

A. Arkhipov, Y. Shan, E. T. Kim, R. O. Dror, and D. E. Shaw, Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family, 2013.

K. Erjala, M. Sundvall, T. T. Junttila, N. Zhang, M. Savisalo et al., Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells, Clin. Cancer Res, vol.12, pp.4103-4111, 2006.

D. L. Wheeler, S. Huang, T. J. Kruser, M. M. Nechrebecki, E. A. Armstrong et al., Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members, Oncogene, vol.27, pp.3944-3956, 2008.

K. M. Quesnelle and J. R. Grandis, Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance, Clin. Cancer Res, vol.17, pp.5935-5944, 2011.

N. Kondo, M. Tsukuda, A. Sakakibara, H. Takahashi, H. Hyakusoku et al., Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines, Int. J. Oncol, vol.40, pp.1805-1812, 2012.

J. Baselga, I. Bradbury, H. Eidtmann, S. Di-cosimo, E. De-azambuja et al., Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial, Lancet, vol.379, pp.633-640, 2012.

C. Hanusch, A. Schneeweiss, S. Loibl, M. Untch, S. Paepke et al., Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70), Clin. Cancer Res, vol.21, pp.2924-2931, 2015.

D. M. Collins, K. Gately, C. Hughes, C. Edwards, A. Davies et al., Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines, Cell. Immunol, vol.319, pp.35-42, 2017.

R. Okita, K. Shimizu, Y. Nojima, T. Yukawa, A. Maeda et al., Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells, Oncol. Rep, vol.34, pp.2864-2870, 2015.

B. Bour,

W. Wasylyk, IGBMC, UMR 7104 CNRS-UdS, U.1258 INSERM

A. C. Jung, , 2019.

C. Oliveras-ferraros, S. Cufi, B. Queralt, A. Vazquez-martin, B. Martin-castillo et al., Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells, Br. J. Cancer, vol.106, pp.1406-1414, 2012.

G. Oshima, J. Wennerberg, T. Yamatodani, E. Kjellen, H. Mineta et al., Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines, J. Cancer Res. Clin. Oncol, vol.138, pp.491-499, 2012.

A. Jedlinski, A. Ansell, A. C. Johansson, and K. Roberg, EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines, J. Oral Pathol. Med, vol.42, pp.26-36, 2013.

C. Jing, Y. H. Jin, Z. You, Q. Qiong, and Z. Jun, Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients, Oncotarget, vol.7, pp.55890-55899, 2016.

D. J. Jonker, C. S. Karapetis, C. Harbison, C. J. O'callaghan, D. Tu et al., Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer, Br. J. Cancer, vol.110, pp.648-655, 2014.

Y. Kogashiwa, H. Inoue, K. Kuba, R. Araki, M. Yasuda et al., Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab, Head Neck, vol.40, pp.2424-2431, 2018.

A. Ianevski, L. He, T. Aittokallio, and J. Tang, SynergyFinder: A web application for analyzing drug combination dose-response matrix data, Bioinformatics, vol.33, pp.2413-2415, 2017.